Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
After two-and-a-half years in stealth mode, Maze Therapeutics unveiled a $191 million series A funding round and a stellar line-up of scientists who aim to discover new biology and new drug targets by systematically mining human genetic databases for genetic modifiers that reduce the impact of disease-causing mutations. The company is, at the same time, establishing a functional genomics platform that it claims will enable the study at a cellular level of the phenotypic consequences of disrupting the genome. Combining these two types of data will, it hopes, lead to new insights into disease biology that can be translated into starting points for drug discovery programs. The general concept is not new, but Maze’s founding team and its backers hold that this is an opportune time to pursue such a strategy at scale because of the simultaneous availability of large volumes of human genomic and associated clinical data and the tools and technologies for conducting detailed phenotypic analyses.